Sanofi (SNY) Interest Coverage Ratio (2009 - 2026)
Sanofi (SNY) posted Interest Coverage Ratio of 48.71 for Q2 2026, up 28.81% sequentially from 68.43 in Q1 2026, and up 80.82% YoY from 26.94 in Q2 2025.
Sanofi (SNY) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Sanofi has reported Interest Coverage Ratio for 18 years, with the latest figure at 48.71 in Q2 2026.
- Quarterly Interest Coverage Ratio rose 80.82% year-over-year to 48.71 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 45.9 (down 22.25% YoY) and the FY2025 annual result came in at 11.27, up 66.72% from the prior year.
- Interest Coverage Ratio advanced to 48.71 in Q2 2026 per SNY's latest filing, from 68.43 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 13.28 in Q2 2024 and troughed at 253.96 in Q2 2025.
- A 5-year average of 73.56 and a median of 56.34 in 2025 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio jumped 123.09% in 2024, then slumped 2012.23% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 134.75 in 2022, then jumped by 74.5% to 34.36 in 2023, then jumped by 40.5% to 20.44 in 2024, then gained by 9.87% to 18.43 in 2025, then sank by 164.37% to 48.71 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 48.71, 68.43, and 18.43 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.44 Bn | 632.68 Bn | 17.26 Bn | 25.41 |
| 2 | AbbVie | 470.20 Bn | 463.63 Bn | 12.70 Bn | - |
| 3 | Merck | 378.55 Bn | 371.41 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 302.90 Bn | 295.21 Bn | 11.24 Bn | 10.28 |
| 5 | Astrazeneca | 258.41 Bn | 253.51 Bn | 12.86 Bn | 7.27 |
| 6 | Amgen | 237.59 Bn | 223.61 Bn | 7.24 Bn | 5.22 |
| 7 | Gilead Sciences | 183.64 Bn | 180.46 Bn | 6.22 Bn | -42.08 |
| 8 | Pfizer | 160.71 Bn | 149.01 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.18 Bn | 102.01 Bn | 8.24 Bn | -2.64 |
| 10 | Sanofi | 55.33 Bn | 47.95 Bn | 10.79 Bn | -50.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.71 |
| Mar 31, 2026 | -68.43 |
| Dec 31, 2025 | -18.43 |
| Sep 30, 2025 | -63.89 |
| Jun 30, 2025 | -253.96 |
| Mar 31, 2025 | -55.15 |
| Dec 31, 2024 | -20.44 |
| Sep 30, 2024 | -52.35 |
| Jun 30, 2024 | 13.28 |
| Mar 31, 2024 | -42.66 |
| Dec 31, 2023 | -34.36 |
| Sep 30, 2023 | -41.19 |
| Jun 30, 2023 | -57.52 |
| Mar 31, 2023 | -71.15 |
| Dec 31, 2022 | -134.75 |
| Sep 30, 2022 | -132.88 |
| Jun 30, 2022 | -116.08 |
| Mar 31, 2022 | -125.47 |
| Dec 31, 2021 | -83.92 |
| Sep 30, 2021 | -129.89 |